Navidea Biopharmaceuticals Inc (NAVB)

[casperboo]

The TASE addition has been a long overdue boost for our underperforming NAVB.

But how long can this pps last in the 2.20s-2.50 without some real MT news or a significant increase in revenues when the Q3 numbers come out? How about that 4694 partnership? The company will need a year in Europe to realize premium pricing? Approval in the EU came more than a year ago. Delay, delay, delay needs to be replaced with SUCCESS, SUCCESS, SUCCESS or the pps will slide under 2.00 again. Not bashing, just very familiar with how classic Larson/Navidea inaction eventually gets recognized by the market (and impatient NAVB investors such as myself).

Q3 Revenue for Navidea of $3,000,000 would be a 50% increase over the $1,980,000 million they had for Q2 - BUT I SERIOUSLY DOUBT THAT Q3 will be anything above $2.5 million. If it is, I will be wrong. But what matters more than my rightness or wrongness is what revenue will move the pps up from here. $3 million has a chance to matter, but does it have a chance to happen for Q3?

I know this much! $3.5 million OR MORE BETTER HAPPEN FOR Q4!